SHP2 is frequently mutated in acute myeloid leukemia (AML) as well as in juvenile myelomonocytic leukemia (JMML), and SHP2 inhibition was established as reducing leukemogenesis in models of genetic or epigenetic mutations (68, 69). Here, PTPN11 is linked to juvenile myelomonocytic leukemia.